Next-generation drugs based on peptidomimetics
Iproteos is a biotechnology company based at the Barcelona Science Park that specializes in the research and development of third-generation drugs for human diseases.
The company’s strategy is based on the creation of novel compounds able to modulate the activity of undruggable targets, such as Protein-Protein Interactions (PPIs). PPIs are involved in many diseases, including those affecting the cardiovascular and central nervous systems and many forms of cancer. Several innovative compounds designed and developed by Iproteos have proven efficacy and are in preclinical phase.
Iproteos has well-established intellectual property. To this end, the company’s activity spans several drug development stages (discovery, preclinical validation, intellectual property patent process, and clinical phase) and subsequent licensing of its intellectual property to pharmaceutical companies.
In addition, Iproteos is supported by IPROTech, an in-house technology platform. Based on the combination of computational techniques, peptide synthesis and evaluation, this technology allows the development of innovative compounds in less time and at a lower cost. IPROTech was awarded the Seal of Excellence by the European Commission.